Volume 14 Number 11/12 November/December 2013
1 December 2013. Related: Editorial.
2013
Guide to HIV and HCV coinfection (November 2013)
1 December 2013. Related: Supplements.
44th Union World Conference on Lung Health, 30 October – 3 November 2013, Paris
1 December 2013. Related: Conference reports.
Preventing and treating TB in children – more baby steps
1 December 2013. Related: Conference reports, Paediatric care, PK and drug interactions, TB coinfection.
14th European AIDS Conference (EACS), 16-19 October 2013, Brussels
1 December 2013. Related: Conference reports.
Dolutegravir superior to darunavir/r at week 48 in open label treatment naïve study
1 December 2013. Related: Conference reports, Antiretrovirals.
GSK744: 24-week results with oral integrase inhibitor planned for once-monthly injections
1 December 2013. Related: Conference reports, Antiretrovirals.
Cenicriviroc: 48 week results compared to efavirenz
1 December 2013. Related: Conference reports, Antiretrovirals.
Approaches to once-daily raltegravir: new formulation likely to require food
1 December 2013. Related: Conference reports, Antiretrovirals.
DSMB stops boosted atazanavir monotherapy study due to virological failure
1 December 2013. Related: Conference reports, Antiretrovirals.
Recreational drug use is common in HIV positive gay men and is extensive in a significant minority
1 December 2013. Related: Conference reports, Antiretrovirals.
Caution against prolonged use of bisphosphonates in patients with mild-moderate fracture risk
1 December 2013. Related: Conference reports, Coinfections and complications.
Osteoporosis triples risk of later fracture in 1000-person US HIV group
1 December 2013. Related: Conference reports, Coinfections and complications.
Bone turnover marker changes early in ART predict bone loss after 96 week
1 December 2013. Related: Conference reports, Coinfections and complications.
Low HDL cholesterol is main lipid abnormality in HIV+/HIV- comparison
1 December 2013. Related: Conference reports, Lipodystrophy and metabolic complications.
Classic risk factors, but not HIV, linked to arterial stiffness in middle-aged
1 December 2013. Related: Conference reports, Coinfections and complications.
Elvitegravir approved in EU: data on food and drug interactions
1 December 2013. Related: Antiretrovirals.
ViiV file 572-trii fixed dose combination in the US: positive opinion to approve dolutegravir in the EU
1 December 2013. Related: Antiretrovirals.
Obama increases US contribution to Global Fund to $5 billion over three years
1 December 2013. Related: Treatment access.
HIV struggle in South Africa undermined by medicine stockouts and mismanagement
1 December 2013. Related: Treatment access.
European guidelines launched at EACS (2013)
1 December 2013. Related: Guidelines.
Paediatric guidelines on the prevention and treatment of OIs (November 2013)
1 December 2013. Related: Paediatric care, Guidelines.
US HIV guidelines update information on integrase inhibitors (Oct 2013)
1 December 2013. Related: Guidelines.
Efavirenz is associated with higher suicide risk in meta-analysis of four ACTG studies
1 December 2013. Related: Side effects.
EU recommends approval of sofosbuvir for HCV
1 December 2013. Related: Hepatitis coinfection.
Compassionate use of declatasvir with sofosbuvir for people in urgent need of HCV treatment
1 December 2013. Related: Hepatitis coinfection.
The little blue pill that can stop HIV: PROUD study enrolling gay men in the UK
1 December 2013. Related: HIV prevention and transmission.
Dual HIV infection in long term nonprogressor elite controllers
1 December 2013. Related: Basic science and immunology.
Online journals
1 December 2013. Related: On the web.
Volume 14 Number 11/12 November/December 2013 PDF
1 December 2013. Related: PDFs.
Southern African treatment guidelines retain CD4 threshold of 350 for starting ART (2013)
1 October 2013. Related: Treatment strategies, Treatment access, Guidelines.
Volume 14 Number 9/10 September/October 2013
1 October 2013. Related: Editorial.
CROI website still blocked
1 October 2013. Related: Treatment alerts.
53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 10-13 September 2013, Denver
1 October 2013. Related: Conference reports.
Raltegravir safe and effective in pregnancy in small French study
1 October 2013. Related: Conference reports, Antiretrovirals, Pregnancy.
Side effects common but mostly mild in women taking higher dose protease inhibitors in pregnancy
1 October 2013. Related: Conference reports, Antiretrovirals, Pregnancy.
Good safety profile with long-acting integrase inhibitor GSK744
1 October 2013. Related: Conference reports, Antiretrovirals.
TAF comparable to TDF in once-daily pill for ART-naive: 48-week results
1 October 2013. Related: Conference reports, Antiretrovirals.
Dolutegravir superior to darunavir at 48 weeks in open-label ART-naive trial
1 October 2013. Related: Conference reports, Antiretrovirals.
7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 30 June – 3 July 2013, Kuala Lumpur
1 October 2013. Related: Conference reports.
High prices for antiretrovirals in middle-income countries outside Africa
1 October 2013. Related: Conference reports, Antiretrovirals, Treatment access.
Comparable efficacy and pregnancy outcomes with boosted atazanavir and lopinavir at standard doses
1 October 2013. Related: Conference reports, Antiretrovirals, Pregnancy.
PrEP gives little extra benefit in attempted conception if male partner is on ART
1 October 2013. Related: Conference reports, Antiretrovirals, Pregnancy.
Cobicistat approved as pharmacokinetic (PK) booster for atazanavir and darunavir in EU prior to the US
1 October 2013. Related: Antiretrovirals.
NHS England approves four-in-one Stribild (Quad) for limited use
1 October 2013. Related: Antiretrovirals.
Dolutegravir approved in the US
1 October 2013. Related: Antiretrovirals.
ViiV goes for gold: US premium pricing may make dolutegravir redundant in the UK
1 October 2013. Related: Antiretrovirals.
From sky high to CHAI* – what needs to be done about dolutegravir pricing?
1 October 2013. Related: Antiretrovirals, Treatment access.
Pharmacokinetics of etravirine with once-daily and twice-daily dosing
1 October 2013. Related: Antiretrovirals, PK and drug interactions.
UK pledges £1 billion for Global Fund
1 October 2013. Related: Treatment access.
France pledges $1.4 billion for Global Fund
1 October 2013. Related: Treatment access.
UNAIDS reports new HIV infections are reduced by one-third compared to 2001
1 October 2013. Related: Treatment access.
Longitudinal changes in weight, lean body mass and bone mineral density in first-line combinations: ACTG 5205 substudy
1 October 2013. Related: Side effects.
Persistence of transmitted drug resistance mutations suggests source partners may be treatment-naive
1 October 2013. Related: HIV prevention and transmission, Drug resistance.
Activists call EU failure to approve delaminid for MDR tuberculosis due to limited data both “myopic and disappointing”
1 October 2013. Related: TB coinfection.
Circulating memory T follicular helper cells correlate with the development of broadly neutralising antibody responses against HIV
1 October 2013. Related: Cure-related research, Basic science and immunology.
HIV self testing to become legal in the UK from April 2014
1 October 2013. Related: HIV prevention and transmission.
Agreement to develop long-acting rilpivirine as PrEP
1 October 2013. Related: HIV prevention and transmission.
Use of ART at baseline by treatment naïve patients in HPTN-052
1 October 2013. Related: HIV prevention and transmission.
UK to lift ban on HIV positive health workers who are on ART with undetectable viral load
1 October 2013. Related: Other news.
CID supplement on HCV and injecting drug users: free online issue
1 October 2013. Related: Hepatitis coinfection, Injecting drug users, On the web.
Volume 14 Number 9/10 September/October 2013 PDF
1 October 2013. Related: PDFs.
Volume 14 Number 7/8 July/August 2013 PDF
26 July 2013. Related: PDFs.
Volume 14 Number 7/8 July/August 2013
25 July 2013. Related: Editorial.
7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 30 June – 3 July 2013, Kuala Lumpur
25 July 2013. Related: Conference reports.